CroFab®: The only FDA-approved product derived exclusively from US snakes and approved to treat all North American pit viper envenomations in adult and pediatric patients.1,2

  • Proven to control local, systemic, and hematologic effects of envenomation1,3*
  • Established performance backed by over 15 years of clinical experience2
  • Over 50,000 patients treated to date2
Strike Back with CroFab®
Strike Back Logo

Strike Back Envenomation Education: Information and resources critical to treating pit viper envenomation.

STAY PREPARED

INITIAL CONTROL FOR SNAKE ENVENOMATION INVOLVES
HALTING LOCAL, SYSTEMIC, AND HEMATOLOGIC EFFECTS1:

Effects Snakes
Local effects +
Systemic effects +
Hematologic effects +
X

Local Effects

SYMPTOMS4

  • Swelling, tenderness, and pain
  • Redness
  • Ecchymosis
  • Bullae or blebs
  • Soft-tissue necrosis

CONSEQUENCES4-7

  • Partial or complete loss of affected limbs
  • Loss of joint functionality
  • Loss or impairment of tactile sensation
  • Infection
  • Cosmetic issues

PREPARE TO STRIKE BACK AGAINST PIT VIPER ENVENOMATION

Triple Control

Gain triple control with CroFab®*

CroFab® is proven to halt local effects, resolve systemic effects, and reduce coagulation abnormalities.1,3

LEARN MORE
Treatment Algorithm

How to Treat a Snakebite

Use the interactive guide with step-by-step instructions on how to treat a snakebite.

TREAT NOW LEARN MORE
Dosing and Administration

Dosing and administration

Dose CroFab® appropriately to gain and continue control of envenomation.1,4

LEARN MORE

How to Order CroFab®

Expert consensus guidelines for stocking of antidotes in
hospitals that provide emergency care9

All hospitals that provide emergency care should stock 12 to 18 vials of CroFab®—enough antidote to treat
one patient for 8 to 24 hours

*Efficacy determined using the snakebite severity score (SSS), a validated objective tool for the clinical evaluation of North American pit viper snakebite in adults. The total score reflects patient evaluation on 6 dimensions: cardiovascular system, local wound, gastrointestinal system, hematologic symptoms, pulmonary system, and central nervous system. The higher the total score, the more severe the snakebite.1


References:

1. CroFab® [prescribing Information]. BTG International Inc; May 2017. 2. Data on file. Conshohocken, PA; BTG International Inc. 2015. 3. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030-2036. 4. Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2. 5. Nelson L, Lewin N, Howland M, et al. Goldfrank’s Toxicologic Emergencies. 9th ed. McGraw Hill Medical; 2010:1601-1609. 6. Ruha AM, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry. J Med Toxicol. 2017;13(4):309-320. 7. Mackessy SP, ed. Handbook of Venoms and Toxins of Reptiles. Boca Raton, FL: CRC Press; 2010. 8. Gold BS, Dard RC, Barish RA. Bites of venomous snakes. N Engl J Med. 2002;347(5):347-356. 9. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.